Correction

This article refers to:

Repurposing FDA-approved drugs as NLRP3 inhibitors against inflammatory diseases: machine learning and molecular simulation approaches

Article title: Repurposing FDA-approved drugs as NLRP3 inhibitors against inflammatory diseases: machine learning and molecular simulation approaches

Authors: Vipul Agarwal, Rajesh Haldhar, Abdurahman Hajinur Hirad, Bilal Ahmed, Sang Beom Han, Anugya Gupta, Vinit Raj and Sangkil Lee

Journal: Journal of Biomolecular Structure and Dynamics

DOI: https://doi.org/10.1080/07391102.2024.2308072

During the final typesetting of this article, the typesetter inadvertently failed to process the Figure 6 correction. This has now been updated and the original article has been republished.

In addition, the grant number under the funding section has been updated as well.

The correct Figure 6 is placed below as well.

Figure 6. RMSD, Protein RMSF, protein interaction and protein-ligand contacts of top docked ADMET favorable FDA-approved compounds (A-B) RMSD (C-D) Protein RMSF, (E-F) protein interaction and (G-H) protein-ligand contacts plots of Empagliflozin and Citicoline over simulations run for 100ns complexed with NLRP3.